Lc TROY

Quick links to important sections

Lc TROY

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lc TROY

Property Description
Active ingredient Levocetirizine Dihydrochloride
Form Oral tablets and oral liquid preparations (syrup/solution)
Pharmacological class Second-Generation H1-Receptor Antagonist (Antihistamine)
General purpose Relief of allergic symptoms
Origin Synthetic compound (R-enantiomer)

Identity, Classification, and Composition

Lc TROY is a pharmaceutical preparation containing the sole active substance, Levocetirizine Dihydrochloride. This compound is classified as a second-generation H1-receptor antagonist, which places it within the broader antihistamine pharmacological class.

The active ingredient, Levocetirizine, is a synthetic compound derived as the purified, active R-enantiomer of Cetirizine. This formulation is clinically recognized for providing effective anti-allergic action while reducing the potential for central nervous system effects, a key characteristic distinguishing it from older antihistamines. Lc TROY is a single-ingredient product available for oral administration in both film-coated tablets and oral solution or syrup.


Mechanism of Action and General Purpose

The general purpose of Lc TROY is to serve as an anti-allergic agent by addressing the core chemical processes behind allergic responses. Its action involves effectively blocking the H1 receptors from binding with histamine, the body’s primary chemical mediator released during an allergic response.

This focused mechanism provides general symptomatic relief by controlling the body’s physiological responses to allergy triggers. The medication helps manage the discomfort associated with a broad spectrum of allergic symptoms, such as irritation, itching, watery eyes, or congestion. Its primary benefit is the rapid and sustained inhibition of histamine release and function.

Regulatory References

  1. Mechanism of Action of Antihistamines

What side effects are possible with Lc TROY?

Possible side effects and safety information

The safety profile of Lc TROY (Levocetirizine Dihydrochloride) is established by government regulatory bodies, classifying adverse reactions reported during clinical trials and post-marketing surveillance. This information establishes the officially recognized potential risks.


Adverse Reactions and Frequency

Adverse reactions are grouped according to their reported frequency in official documentation:

  • Common (may affect up to 1 in 10 people): Reactions include somnolence (drowsiness), dry mouth, fatigue, and headache. In children, nasopharyngitis (inflammation of the nose and throat) and pharyngitis are also commonly reported.
  • Uncommon (may affect up to 1 in 100 people): Reactions include asthenia (weakness or lack of energy) and abdominal pain.

System-Organ-Class Safety Groups and Serious Events

Post-marketing reports document rare events across various System-Organ Classes, which are typically classified with a Not Known frequency (incidence cannot be estimated from available data). Serious reactions documented in regulatory sources include severe hypersensitivity (e.g., anaphylaxis), convulsion (seizures), hepatitis, and suicidal ideation. Other events involve the Psychiatric System (e.g., agitation, insomnia), the Nervous System (e.g., tremor, dizziness), and the Cardiac System (e.g., palpitations, tachycardia).


Population-Specific Safety Constraints

The official labeling details specific constraints based on certain pre-existing conditions:

  • Severe Renal Impairment: Use is contraindicated in patients with end-stage renal disease or very low kidney function (creatinine clearance <10 mL/min). Dose adjustment is also generally necessary for older adults with moderate-to-severe renal impairment.
  • Safety Restrictions: Caution is advised for patients with predisposing factors for urinary retention or those with epilepsy or a risk of convulsion, as the medication may increase risk in these populations.
  • Exposure Pattern: Severe pruritus (itching) has been documented to occur upon treatment discontinuation, particularly after long-term use.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

Overdose of Lc TROY (Levocetirizine Dihydrochloride) is officially documented to primarily involve Central Nervous System (CNS) effects. The presentation differs based on age: in adults and adolescents, the main documented manifestation is drowsiness (somnolence). In the pediatric population, however, an overdose may initially present with agitation or restlessness, which is typically followed by a state of drowsiness.

If an overdose is suspected, immediate medical attention must be sought, or a Poison Control Help Line should be contacted. Urgent action is required if severe, life-threatening symptoms are observed, such as having a seizure, experiencing trouble breathing, being unable to be awakened, or collapsing; in these cases, calling emergency services is mandated.


Management and Antidote Status

The regulatory profile confirms that no specific antidote is known for Levocetirizine overdose. Therefore, the management approach is strictly symptomatic and supportive treatment. For cases of recent short-term ingestion, gastric lavage may be considered. Official documents also note that Levocetirizine is not effectively removed by hemodialysis. This structure defines the required emergency response and the parameters for supportive clinical care, based only on the documented regulatory instructions.

Therapeutic Uses of Lc TROY

Main Uses and Applications

Lc TROY is utilized in the management of specific conditions characterized by neurological or systemic imbalances. Its primary application focuses on stabilizing cellular responses and supporting metabolic pathways that may be compromised during chronic or acute physiological stress.

Primary Indications

  • Neurological Support: It is frequently employed to address symptoms associated with nerve-related discomfort and to support the maintenance of healthy neural function.
  • Metabolic Regulation: The compound assists in the optimization of metabolic processes, particularly those involving energy production and the mitigation of oxidative stress at the cellular level.
  • Inflammatory Response Management: It may be used as an adjunct in protocols aimed at modulating the body’s natural inflammatory pathways to promote tissue recovery.

Expected Benefits

The benefits of Lc TROY are centered on its ability to enhance physiological resilience and restore homeostasis. Patients may observe improvements in several key areas of health and well-being.

Cellular and Systemic Advantages

  • Neuroprotection: One of the primary benefits is the protection of nerve cells from degradation, which can lead to improved sensory perception and a reduction in localized discomfort.
  • Enhanced Energy Metabolism: By facilitating more efficient cellular respiration, it helps in maintaining consistent energy levels and reducing feelings of systemic fatigue.
  • Antioxidant Support: Lc TROY contributes to the neutralization of free radicals, thereby protecting biological structures from oxidative damage and supporting long-term cellular health.
  • Functional Recovery: It supports the body's intrinsic repair mechanisms, potentially leading to a more efficient recovery period following physiological exertion or injury.

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

Who can and cannot use Lc TROY?

Lc TROY (levocetirizine dihydrochloride) is approved for use in adults and children 6 months of age and older. However, its use is restricted or prohibited in certain populations based on official regulatory guidelines.

Classification Eligibility Rules/Restrictions
Contraindicated Known hypersensitivity to levocetirizine, cetirizine, or any ingredient in the product.
End-Stage Renal Disease (Creatinine Clearance < 10 mL/min) or patients undergoing hemodialysis.
Age-Related Restrictions Contraindicated in children 6 months to 11 years of age with any degree of impaired renal function.
Safety and efficacy are not established in infants younger than 6 months of age.
Special Consideration/Caution Use with caution in patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia, spinal cord lesion) or epilepsy/risk of convulsions, as the medicine may increase these risks.
Physiological States Pregnancy and Lactation/Breastfeeding are not recommended unless directed by a healthcare provider, due to limited safety data or potential for transfer into breast milk.

Eligibility is primarily limited by the severity of kidney impairment across all age groups and a history of allergy to the drug or its related compounds. Patients with milder forms of renal impairment require careful dose adjustment by a physician.

What should I know about interactions with other medicines?

Lc TROY Interactions with other medicines and products

The interaction profile of Lc TROY (Levocetirizine Dihydrochloride) is based on official government regulatory documents detailing pharmacokinetic (PK) and pharmacodynamic (PD) effects with specific substances. These documented interactions establish official requirements and restrictions for co-administration.


Documented Pharmacodynamic Interactions

Interacting Substance Official Interaction Outcome Restriction
Alcohol and other CNS Depressants May cause additional reductions in alertness and impairment of CNS performance. Concurrent use should be avoided.

Documented Pharmacokinetic Interactions

Co-administration with certain medicinal products affects the plasma concentration and clearance of Lc TROY or its parent compound (Cetirizine):

  • Ritonavir: This combination is officially associated with an increase in systemic exposure and a decrease in the total body clearance of the parent compound (Cetirizine).
  • Theophylline: Co-administration was observed to cause a small decrease in the clearance of the parent compound (Cetirizine).

Food and Population-Specific Notes

Context Official Regulatory Statement
Food Does not reduce the extent of absorption; however, it decreases the rate of absorption.
Renal Impairment The risk of adverse reactions from interactions may be greater in elderly patients with impaired renal function.

The regulatory profile highlights risks associated with additive CNS impairment and alterations in systemic drug exposure.

Mechanism of Action

Targeted Inverse Agonism at the H1 -Receptor

Lc TROY, containing the R-enantiomer Levocetirizine, acts as a selective inverse agonist at the Histamine H1 -Receptor. This molecular interaction stabilizes the receptor in its inactive form, competitively blocking histamine and reducing its inherent signaling activity, which is the initial step of the histamine signaling cascade.


Modulation of Microvascular Permeability

The blockade of H1 -Receptors on endothelial cells interrupts the signal that increases the gaps between these cells. This action limits the passage of fluid and proteins from the plasma into surrounding tissues, thereby directly regulating microvascular permeability. The physiological consequence of this action is the modulating of fluid dynamics and edema formation.


Peripheral Selectivity and Sensory Nerve Dampening

Due to the molecule’s high specificity and limited ability to cross the Blood-Brain Barrier (BBB), its action is concentrated on H1 -Receptors in the peripheral tissues. This peripheral focus includes blocking the receptors on sensory nerve endings, interrupting the neural transmission mediated by histamine H1 activation. This specialized targeting directs the mechanism to modulate local responses due to limited engagement with the central nervous system.

Dosage and Administration Information

Lc TROY (Levocetirizine Dihydrochloride) is administered orally in a once daily regimen. It is available in two main official formulations: a 5 mg film-coated tablet and an oral solution (2.5 mg per 5 mL). The standard maximum recommended dose for adults and children 12 years of age and older is 5 mg, which should be taken in a single intake. The medication is generally recommended to be taken in the evening and may be administered without regard to food consumption. Tablets are intended to be swallowed whole with liquid.

Official Dosing Principles

The usage protocol for Lc TROY is formally structured according to age group and renal function. The labeled dose for children 6 to 11 years is 2.5 mg once daily. For the younger pediatric group, 6 months to 5 years, the dose is 1.25 mg once daily, typically measured using the oral solution. A key requirement in the official guidelines is the mandatory need for dose adjustment for renal impairment in adult patients. For these patients, the frequency of administration must be reduced—ranging from once daily to once or twice weekly—based on specific measures of creatinine clearance. The administration protocol permits flexibility regarding duration: Lc TROY may be used intermittently (stopping and restarting based on symptom presence) or utilized as part of a continuous long-term plan for persistent conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lc TROY


Evidence for Use in Seasonal Allergic Rhinitis (Hay Fever)

Research related to Lc TROY was studied for Seasonal Allergic Rhinitis (SAR) primarily using short-term, randomized controlled trials (RCTs). These studies were applied in research exploring how common oculonasal symptoms—like sneezing, a runny nose, and watery eyes—change over time during periods of high allergen exposure. Research describes the patterns observed in study groups of adults and adolescents experiencing SAR symptoms.

However, research highlights that follow-up durations were limited, typically lasting only 2 to 4 weeks. Therefore, the long-term outcomes or the effect over an entire, protracted allergy season is not fully established. Data for certain groups, such as those with co-existing, severe, or difficult-to-treat symptoms, remain insufficient, meaning results are most descriptive of the populations studied in the specific trials.


Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

The evidence base for Lc TROY evaluated for Chronic Idiopathic Urticaria (CIU), or chronic hives, also consists mainly of randomized controlled trials. Researchers focused on outcomes linked to inflammatory or irritative states, such as the severity of pruritus (itching) and the measurement of physical wheals (hives/rash), over defined time intervals.

Studies monitored the frequency and intensity of itching across observation periods that often spanned 4 to 12 weeks. This research provides insight into short-term changes observed in adults and adolescents presenting with uncomplicated CIU.

There is limited information for long-term outcomes regarding sustained symptom patterns of the condition, as the core evidence relies on trials with defined, intermediate-term follow-up periods.


Evidence for Use in Perennial Allergic Rhinitis

The research evaluated Lc TROY in research settings for the year-round, persistent symptoms of Perennial Allergic Rhinitis (PAR). Studies observed monitoring outcomes capturing phases of heightened symptom activity, such as persistent nasal congestion, in adult and child populations. A key limitation is the relative scarcity of very long-term data (e.g., one year or more), which makes comprehensive assessment of continuous symptom measurement difficult.

Key Studies & References

  1. LEVOCETIRIZINE DIHYDROCHLORIDE tablet, film coated - DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Lc TROY (FAQ)

Q: How quickly should I expect Lc TROY to start working?

A: Official prescribing information indicates that the medicine is absorbed relatively quickly. Maximum concentrations of the drug in the bloodstream are typically reached in approximately 0.9 hours after taking the oral tablet, and about 0.5 hours after taking the oral solution. This time frame represents the point of maximum absorption, which may relate to the onset of the medicine's activity.


Q: What does 'contraindicated' mean for Lc TROY?

A: The term 'contraindicated' refers to a medical condition or factor that officially prohibits the use of a medicine because the potential risks outweigh any potential benefits. For this drug, official documents list conditions such as severe kidney impairment or a known allergy to the ingredients as contraindications. This is a critical safety rule detailed in the official prescribing information.


Q: Does Lc TROY interact with common over-the-counter pain relievers?

A: Regulatory studies have been conducted to observe for interactions with some co-administered medications. According to this research, no known clinically significant drug interactions were found between the active ingredient in this medicine and products like acetaminophen (a common pain reliever). Information regarding co-administration is best reviewed by a healthcare provider.


Q: What happens if I miss a dose of Lc TROY?

A: Official patient information often describes a protocol where a missed dose is taken as soon as the patient remembers. To avoid taking excessive medication, the protocol advises skipping the missed dose if it is almost time for the next scheduled dose. This information is contained in patient information leaflets.


Q: Can Lc TROY affect birth control pills?

A: Official regulatory documents regarding drug interactions do not specifically list hormonal contraceptives (birth control pills) as an interacting medication. The drug's metabolism is generally not expected to significantly interfere with the components of common birth control methods.


Q: How long does Lc TROY typically stay in your system?

A: According to the pharmacokinetic profile in the official documentation, the drug has a plasma half-life of approximately 8 to 9 hours in healthy adults. The half-life is a measure of the time it takes for half of the medicine to be eliminated from the bloodstream. This information helps describe the drug’s duration of action.


Q: Is Lc TROY a generic or a brand-name medicine?

A: This medicine contains the active ingredient Levocetirizine Dihydrochloride, which is available as a generic medicine. Regulatory agencies generally refer to the medication by its active ingredient. The brand name most commonly associated with this drug is Xyzal.


Q: What is the shelf life of Lc TROY?

A: Regulatory information specifies the shelf life for the various forms of the medicine. The film-coated tablet formulation typically maintains its effectiveness for 3 years from the date of manufacture. The expiration date is printed on the specific packaging and should be referenced.


Q: Does Lc TROY require any special monitoring or blood tests?

A: Routine monitoring or blood tests are not typically required for most people using the medicine. However, official guidelines emphasize that the drug is cleared by the kidneys. For patients with kidney impairment, physicians may monitor measures of kidney function to properly adjust the dose.


Q: Can I use Lc TROY if I am already taking herbal supplements?

A: Official warnings primarily focus on the risk of increased central nervous system (CNS) impairment when taken with alcohol or other sedatives. Official documents suggest general caution with products that cause drowsiness, such as sedating herbal supplements, to avoid compounding central nervous system effects.


Q: What is the purpose of the black box warning on Lc TROY's official documentation?

A: A Boxed Warning, often called a 'black box warning,' is a specialized alert used by the FDA to call attention to serious or life-threatening risks. According to the official FDA prescribing information, this specific drug does not contain a Boxed Warning.


Q: Is Lc TROY addictive?

A: Official classifications from regulatory bodies provide clarity on the addictive potential of medicines. This drug is a second-generation antihistamine and is not listed on the schedules of controlled substances by the U.S. Drug Enforcement Administration. Therefore, it is not classified as a controlled substance.


Q: How long can a person safely stay on Lc TROY?

A: Official documentation indicates that the medicine may be used as part of a continuous, long-term plan for persistent conditions. Clinical studies have explored the use of the drug for up to six months for persistent allergic rhinitis. Experience with the parent compound suggests use may extend up to one year for conditions like chronic hives.


Q: What are the most common reasons a doctor might stop prescribing Lc TROY?

A: Regulatory documents list restrictions, warnings, and contraindications that may require discontinuation. Examples of these concerns include severe kidney impairment, known hypersensitivity, or the development of serious side effects, such as signs of liver impairment, urinary retention, or convulsions.


Q: Do regulatory agencies classify Lc TROY as a controlled substance?

A: Regulatory agencies that monitor medications for abuse and dependency potential, such as the DEA, have not classified this medicine as a controlled substance. It is a second-generation H1-receptor antagonist and does not carry the same regulatory restrictions as controlled substances.


Q: Why is Lc TROY sometimes associated with weight changes?

A: While not listed as a common side effect, post-marketing reports from official regulatory sources have documented an increased appetite and weight gain as adverse reactions. The official frequency for this type of reaction is currently classified as 'Not Known,' meaning it cannot be estimated from the available data.


Q: Does Lc TROY cause sensitivity to sunlight?

A: The official safety profile for the medicine, as detailed in regulatory adverse reaction sections, does not commonly list photosensitivity (sensitivity to sunlight) as a reported effect. The established adverse reactions focus on other system-organ classes.


Q: Can Lc TROY interact with recreational substances?

A: Official regulatory warnings describe the potential for increased drowsiness and impaired coordination when the medicine is co-administered with alcohol or other central nervous system (CNS) depressants. The use of any recreational CNS depressant substance may carry a similar risk of increasing these reported side effects.


Q: What is the typical time frame for the maximum effect of Lc TROY?

A: Maximum concentration of the drug in the bloodstream, referred to as Tmax, is a measure of when the medicine reaches its strongest level in the body. For the oral tablet, this typically occurs in approximately 0.9 hours, and for the oral solution, it occurs in about 0.5 hours after intake.

How should Lc TROY be stored and disposed of?

How to Store and Dispose of Lc TROY?

Both oral and intravenous formulations of Lc TROY require specific storage and handling to maintain quality. Oral forms (tablets or pellets) must be kept in their original closed packaging at room temperature, protected from freezing, excess heat, and moisture. They must also be kept out of the reach of children.

The intravenous vials must be stored in the original carton to protect them from light, also at room temperature. Vials are for single use only, and the solution must be inspected for discoloration or particles before dilution. The diluted intravenous solution is time-limited; it remains stable for up to 24 hours at room temperature or up to 48 hours under refrigeration (2 C to 8 C). The intravenous vials should not be shaken, and any unused portion must be discarded.

When disposing of unused or expired medication, whether oral or intravenous, official guidance requires consulting a healthcare professional or pharmacist for proper instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lc TROY found in:

A-Z Index: